Engimmune Therapeutics Revenue

Biotechnology Research • Allschwil, Basel-Country, Switzerland • 21-50 Employees

Engimmune Therapeutics revenue & valuation

Annual revenue	$2,309,985
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$7,400,000
Total funding	$15,800,000

Key Contacts at Engimmune Therapeutics

Lars Nieba

Ceo

Lars Nieba

Chief Executive Officer

Company overview

Headquarters	Hegenheimermattweg 167a, Allschwil, Basel-Country 4123, CH
Website	engimmune.com
Keywords	Biotechnology, Oncology, Machine Learning, Immunotherapy, Immunology, T Cell Therapy
Founded	2021
Employees	21-50
Socials

Engimmune Therapeutics Email Formats

Engimmune Therapeutics uses 2 email formats. The most common is {first initial}.{last name} (e.g., j.doe@engimmune.com), used 50% of the time.

Format	Example	Percentage
{first initial}.{last name}	j.doe@engimmune.com	50%
{first name}.{last name}	john.doe@engimmune.com	50%

About Engimmune Therapeutics

Engimmune is an immunotherapy company utilising cutting-edge methods for the development of T-cell receptor (TCR)-based immunotherapies including T cell therapies and biologics. By applying our unique protein engineering toolbox we have established and continue to develop proprietary high-throughput technology platforms enabling the discovery of highly potent and safe TCR-based cell therapies and biotherapeutics, thus covering the entire TCR discovery value chain. Operating as a platform technology and product development company, our vision is to become a globally leading provider of best-in-class TCR-based therapeutics for the treatment of serious human diseases with high unmet medical need, with a particular focus on oncology. Engimmune is based in a brand new science park in Allschwill, Basel in Switzerland

Employees by Management Level

Total employees: 21-50

Seniority

Employees

Senior

Entry

C-Suite

Employees by Department

Engimmune Therapeutics has 16 employees across 4 departments.

Departments

Number of employees

Funding Data

Explore Engimmune Therapeutics's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2022-06-03	3	$15,800,000

Funding Insights

$15,800,000

Total funding amount

$15,800,000

Most recent funding amount

Number of funding rounds

Engimmune Therapeutics Tech Stack

Discover the technologies and tools that power Engimmune Therapeutics's digital infrastructure, from frameworks to analytics platforms.

Google Workspace

Lodash

JavaScript libraries

Sentry

Issue trackers

Sirvoy

Appointment scheduling

Wix

Blogs

HTTP/3

Miscellaneous

HSTS

Security

Open Graph

Miscellaneous

React

JavaScript frameworks

Google Cloud

IaaS

Google Cloud CDN

CDN

Envoy

Reverse proxies

Frequently asked questions

Engimmune Therapeutics is located in Allschwil, Basel-Country, CH.

Engimmune Therapeutics generates an estimated annual revenue of $2,309,985. This revenue figure reflects the company's market position and business performance in its industry.

Engimmune Therapeutics has an estimated valuation of $7,400,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Engimmune Therapeutics was founded in 2021, making it 5 years old. The company has established itself as a significant player in its industry over this time.

Engimmune Therapeutics has approximately 21-50 employees. The company continues to grow its workforce to support its business operations and expansion.

Engimmune Therapeutics has raised a total of $15,800,000 across 1 funding rounds. This investment has helped the company grow and expand its operations.

Key Contacts at Engimmune Therapeutics

Lars Nieba

Ceo

Lars Nieba

Chief Executive Officer

4.8

40,000 users